DNA synthesis inhibitors: Metronidazole

Last updated: June 18, 2025

DNA synthesis inhibitors: Metronidazole

(S1) PBL Exam 1

(S1) PBL Exam 1

Osteoporosis
Paget disease of bone
Osteomalacia and rickets
Inflammation
Phosphate, calcium and magnesium homeostasis
Bone remodeling and repair
Vitamin D
Bone disorders: Pathology review
Parathyroid conditions and calcium imbalance: Clinical
Parathyroid hormone
Calcitonin
Hyperparathyroidism
Cytokines
Leukocyte adhesion deficiency
Complement deficiency
Pediatric bone and joint infections: Clinical
Osteomyelitis
Septic arthritis
Bacterial structure and functions
Topoisomerase inhibitors
DNA synthesis inhibitors: Fluoroquinolones
DNA synthesis inhibitors: Metronidazole
Protein synthesis inhibitors: Tetracyclines
Protein synthesis inhibitors: Aminoglycosides
Miscellaneous protein synthesis inhibitors
Skin and soft tissue infections: Clinical
Cell wall synthesis inhibitors: Penicillins
Miscellaneous cell wall synthesis inhibitors
Cell wall synthesis inhibitors: Cephalosporins
Cellulitis
Erysipelas
Impetigo
Necrotizing fasciitis
Folliculitis
Varicella zoster virus
Sporothrix schenckii
Obstructive lung diseases: Pathology review
Asthma
Bronchiectasis
Cystic fibrosis: Pathology review
Cystic fibrosis: Clinical
Cystic fibrosis
Chronic obstructive pulmonary disease (COPD): Clinical
Emphysema
Alpha 1-antitrypsin deficiency
Acid-base map and compensatory mechanisms
Acid-base disturbances: Pathology review
The role of the kidney in acid-base balance
Tubular reabsorption and secretion of weak acids and bases
Buffering and Henderson-Hasselbalch equation
Respiratory acidosis
Metabolic acidosis
Plasma anion gap
Respiratory alkalosis
Metabolic alkalosis
Mendelian genetics and punnett squares
Complement system
Compliance of lungs and chest wall
Lung volumes and capacities
Ventilation-perfusion ratios and V/Q mismatch
Acute respiratory distress syndrome
Bronchodilators: Beta 2-agonists and muscarinic antagonists
Alveolar surface tension and surfactant
Anatomic and physiologic dead space
Ventilation
Airflow, pressure, and resistance
Pleural effusion
Pneumothorax
Mesothelioma
Anatomy of the pleura
Pleural effusion, pneumothorax, hemothorax and atelectasis: Pathology review
Anatomy clinical correlates: Pleura and lungs
Regulation of pulmonary blood flow
Gas exchange in the lungs, blood and tissues
Diffusion-limited and perfusion-limited gas exchange
Zones of pulmonary blood flow
Carbon dioxide transport in blood
Oxygen-hemoglobin dissociation curve
Oxygen binding capacity and oxygen content
Sleep apnea
Pulmonary hypertension
Apnea, hypoventilation and pulmonary hypertension: Pathology review
Pulmonary embolism
Platelet plug formation (primary hemostasis)
Coagulation (secondary hemostasis)
Clot retraction and fibrinolysis
Role of Vitamin K in coagulation
Factor V Leiden
Disseminated intravascular coagulation
Protein C deficiency
Antiphospholipid syndrome
Heparin-induced thrombocytopenia
Antiplatelet medications
Anticoagulants: Warfarin
Anticoagulants: Heparin
Anticoagulants: Direct factor inhibitors
Chronic bronchitis
Iron deficiency anemia
Vitamin B12 deficiency
Autoimmune hemolytic anemia
Glucose-6-phosphate dehydrogenase (G6PD) deficiency
Beta-thalassemia
Alpha-thalassemia
Phenylketonuria (NORD)
Galactosemia

Transcript

Watch video only

DNA synthesis inhibitors are a group of antibiotics that target the synthesis of DNA in bacteria and other organisms. Metronidazole, a 5-nitroimidazole, prevents the synthesis of nucleic acids, which are the building blocks of DNA, and is effective against many bacteria and protozoans.

Metronidazole and related 5-nitroimidazoles are relatively nontoxic to humans. This is because in order to function, they need to be reduced by a protein called ferredoxin, which contains sulfur and iron. This protein is commonly found in anaerobic bacteria and protozoans, but is not as available in humans and aerobic bacteria. Now, this protein can donate an electron to metronidazole, causing it to form free radicals which will damage the DNA, causing it to fragment. Without the DNA as a template, the organism can’t synthesize any more nucleic acids like DNA or mRNA, which will lead to cell death.

Metronidazole can be taken orally, but it’s also available in an IV form and as topical creams. It penetrates well into body tissues and fluids, including vaginal secretions, seminal fluid, saliva, breast milk, cerebrospinal fluid, and crosses over the placenta.

This medication can treat many anaerobic bacterial infections like Clostridioides difficile, which can cause pseudomembranous enterocolitis in people taking other antibiotics. Another common organism treated by this medication is Helicobacter pylori, a common bacteria that causes gastritis and peptic ulcers. However, it should be used in combination with other antimicrobials and proton pump inhibitors as part of a triple therapy for the best outcome when treating this condition. Next, Gardnerella vaginalis and other anaerobes that can cause bacterial vaginosis are all treated by metronidazole.

For protozoan infections, it’s the medication of choice for amoebiasis, an infection of the gut caused by Entamoeba histolytica. It’s the medication of choice against Trichomonas vaginalis as well, which causes vaginal trichomoniasis. Finally, metronidazole is highly effective against giardiasis, or beaver fever, which is an infection of the gut caused by Giardia lamblia.

Metronidazole is metabolized in the liver and it’s an inhibitor of CYP450 enzymes, so it can slow down the metabolism of other medications, like warfarin, which are also broken down by this enzyme.

Common side effects of metronidazole include decreased appetite, nausea, a metallic taste in the mouth, headaches, and stomach cramps.

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review, 12th ed. © (ISBN-13: 978-1259641022) " Katzung (2018 )
  2. "Rang & Dale’s Pharmacology, 9th ed,. © (ISBN-13: 978-0702074486) " Ritter (2019 )
  3. "Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 13th ed. (ISBN-13: 978-1259584732 " Brunton
  4. "Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). 66(7), e1-e48. " Clinical Infectious Diseases (2018)
  5. "Bacterial Vaginosis: Review of Treatment Options and Potential Clinical Indications for Therapy. 28(s1), S57-S65. " Clinical Infectious Diseases (1999)
  6. "Sudden Death Due to Metronidazole/Ethanol Interaction. 17(4), 343-346." The American Journal of Forensic Medicine and Pathology (1996)
  7. "A Comparison of Vancomycin and Metronidazole for the Treatment of Clostridium difficile-Associated Diarrhea, Stratified by Disease Severity. 45(3), 302-307. " Clinical Infectious Diseases (2007)
  8. "Nitroimidazole drugs-action and resistance mechanisms I. Mechanism of action. Journal of Antimicrobial 31(1), 9-20. " Chemotherapy (1993)